Literature DB >> 8573188

Reduction of lipoic acid by lipoamide dehydrogenase.

G P Biewenga1, M A Dorstijn, J V Verhagen, G R Haenen, A Bast.   

Abstract

Racemic lipoic acid is therapeutically applied in pathologies in which free radicals are involved. The in vivo reduction of lipoic acid may play an essential role in its antioxidant effect. It was found that mitochondrial lipoamide dehydrogenase (LipDH, EC 1.8.1.4.) reduces the R-enantiomer 28 times faster than the S-enantiomer of lipoic acid. Moreover, it was observed that the metabolites of lipoic acid, bisnor-, tetranor-, and beta-lipoic acid are poor substrates of LipDH. S-lipoic acid inhibits the reduction of the R enantiomer only at relatively high concentrations. The reduction of R-lipoic acid by mitochondria-rich tissues may proceed smoothly, even if the racemic mixture is applied. This is of importance in elucidating the molecular mechanism of the pharmacotherapeutic effect of lipoic acid.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8573188     DOI: 10.1016/0006-2952(95)02124-8

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  11 in total

1.  Complementary and alternative medicine for the treatment of multiple sclerosis.

Authors:  Vijayshree Yadav; Lynne Shinto; Dennis Bourdette
Journal:  Expert Rev Clin Immunol       Date:  2010-05       Impact factor: 4.473

Review 2.  Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential.

Authors:  Kate Petersen Shay; Régis F Moreau; Eric J Smith; Anthony R Smith; Tory M Hagen
Journal:  Biochim Biophys Acta       Date:  2009-08-04

3.  Effects of lipoic acid on walking performance, gait, and balance in secondary progressive multiple sclerosis.

Authors:  Bryan D Loy; Brett W Fling; Fay B Horak; Dennis N Bourdette; Rebecca I Spain
Journal:  Complement Ther Med       Date:  2018-09-22       Impact factor: 2.446

4.  Pharmacokinetic study of lipoic acid in multiple sclerosis: comparing mice and human pharmacokinetic parameters.

Authors:  Vijayshree Yadav; Gail H Marracci; Myrna Y Munar; Ganesh Cherala; Lauren E Stuber; Lilia Alvarez; Lynne Shinto; Dennis R Koop; Dennis N Bourdette
Journal:  Mult Scler       Date:  2010-02-11       Impact factor: 6.312

5.  Glutathione-dependent thioredoxin reduction and lipoamide system support in-vitro mammalian ribonucleotide reductase catalysis: a possible antioxidant redundancy.

Authors:  Ajanta Chatterji; Kumar Sachin; Rajib Sengupta
Journal:  Mol Biol Rep       Date:  2022-06-02       Impact factor: 2.742

6.  A direct and continuous assay for the determination of thioredoxin reductase activity in cell lysates.

Authors:  Brian Cunniff; Gregg W Snider; Nicholas Fredette; Robert J Hondal; Nicholas H Heintz
Journal:  Anal Biochem       Date:  2013-08-21       Impact factor: 3.365

Review 7.  Lipoic acid. Kinetics and pluripotent biological properties and derivatives.

Authors:  Panagiotis Theodosis-Nobelos; Georgios Papagiouvannis; Paraskevi Tziona; Eleni A Rekka
Journal:  Mol Biol Rep       Date:  2021-08-22       Impact factor: 2.316

8.  Oxidative modification of lipoic acid by HNE in Alzheimer disease brain.

Authors:  Sarita S Hardas; Rukhsana Sultana; Amy M Clark; Tina L Beckett; Luke I Szweda; M Paul Murphy; D Allan Butterfield
Journal:  Redox Biol       Date:  2013-01-30       Impact factor: 11.799

9.  Lipoic acid in secondary progressive MS: A randomized controlled pilot trial.

Authors:  Rebecca Spain; Katherine Powers; Charles Murchison; Elizabeth Heriza; Kimberly Winges; Vijayshree Yadav; Michelle Cameron; Ed Kim; Fay Horak; Jack Simon; Dennis Bourdette
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2017-06-28

10.  Early alpha-lipoic acid therapy protects from degeneration of the inner retinal layers and vision loss in an experimental autoimmune encephalomyelitis-optic neuritis model.

Authors:  Michael Dietrich; Niklas Helling; Alexander Hilla; Annemarie Heskamp; Andrea Issberner; Thomas Hildebrandt; Zippora Kohne; Patrick Küry; Carsten Berndt; Orhan Aktas; Dietmar Fischer; Hans-Peter Hartung; Philipp Albrecht
Journal:  J Neuroinflammation       Date:  2018-03-07       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.